Unibest

Pipeline Database

UB618

Sildenafil Citrate Tablets

UB618

ProductSildenafil Citrate Tablets
Strength50mg; 100mg
IndicationsErectile dysfunction
TherapeuticsMen's Health
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule

Exclusive Summary

  • Sildenafil's patents have long expired, leading to a mature global generic market where it maintains huge demand for erectile dysfunction (ED) treatment through competitive pricing and distribution channels.
  • ED is highly prevalent worldwide, increasing with age, affecting over 300 million men globally, driving continuous market expansion.
  • Sildenafil is listed on the WHO Essential Medicines List and recommended as a first-line treatment for ED, demonstrating strong clinical value and guideline endorsement.
  • Chinese generics can stand out in the global market through high-quality production compliant with ICH standards, international registration experience, and competitive cost advantages.
  • The product is suitable for DTC or offline channel distribution, exhibiting high market penetration and long-term stable demand with excellent commercial returns.

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →